替格瑞洛对急性冠脉综合征患者安全性和有效性的初步评价被引量：2

Effect and Safety of Ticagrelor on Patients with Acute Coronary Syndrome

下载PDF

导出

摘要目的:观察口服替格瑞洛对急性冠脉综合征(ACS)的临床疗效及安全性。方法:选择我院ACS患者196例,按入院顺序随机分为对照组(氯吡格雷组)98例和治疗组(替格瑞洛组)98例,观察6个月,观察2组患者主要不良心血管事件(MACE)及治疗期间并发症发生以及对肝肾功能血尿酸的影响情况。结果:氯吡格雷组MACE发生率明显大于替格瑞洛组(P<0.05);两组均无严重出血并发症,轻度出血发生率差异无统计学意义(P>0.05);替格瑞洛组有5例因呼吸困难、乏力而停药;两组对肝功能(丙氨酸氨基转移酶,ALT)肾功能(血肌酐,Cr)及血尿酸(UA)无明显影响,P>0.05。结论:替格瑞洛治疗ACS,可明显减少MACE发生率,对严重出血风险无增加,临床应用安全有效。 Objective： To observe the effect of oral administration of ticagrelor in patients with acute coronary syndrome（ACS） clinical efficacy and safety. Methods： 196 cases of ACS patients in our hospital, into control group of 98 cases（clopidogrel group） and treatment group（the effect of ticagrelor group 98 cases were randomized according to the order of admission, 6 months observation observed 2 groups of patients with major adverse cardiovascular events（MACE） and during the treatment of complication, and the influence on the blood uric acid in the liver and kidney function. Results： In the clopidogrel group mace rate was significantly greater than that of ticagrelor group（P〈0.05）; two groups had no serious bleeding complications, mild hemorrhage formation rate difference was not statistically significant（P〉0.05）; ticagrelor group have 5 patients with dyspnea, weakness, and withdrawal; two groups of liver function（alanine aminotransferase, ALT）, renal function（serum creatinine（CR） and blood uric acid（UA） without significant effect（P〉0.05）. Conclusion： The treatment of ACS for Grillo can significantly reduce the incidence of MACE, and can not increase the risk of severe bleeding, safe and effective clinical application.

作者曲华清唐强王智颜东陈学智唐群忠刘坤

机构地区北京大学首钢医院心内科

出处《中国医药导刊》 2015年第7期701-702,704,共3页 Chinese Journal of Medicinal Guide

关键词替格瑞洛急性冠脉综合征临床疗效 Ticagrelor Acute Coronary Syndrome Clinical efficacy

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献14

1高润霖,杨新春,李延辉.急性冠脉综合征.北京:人民卫生出版社,2009:5-6.
2Blindt R,Stellbrink K,Taeye A,et al.The significance of vasodilator- stimulated phosphoprotein for risk stratification of stent thrombosis,Thromb Haemost,2007;98:1329-1334.
3Shand JA,Menown IB,Storey RF.Ticagrelar from concept to evaluation. Biomark Med,2011 ;5:53-62.
4Abtahian F, Yonetsu T, Vergallo R,et al. Ticagrelar immediately prior to stenting is associated with smaller residual thrombus in patients with acute coronary syndrome.Int J Cardial,2013;168(3):3099-3101.
5Steg PG,Harrington RA,Emanuelsson H,et al. Stent thrombus with Ticagrelar Versus Clopidogrel in patients with Acute Coronary Syndromes:An analysis from the prospective,randomized PLATO Trial. Circulation,2013; 128:1055-1065.
6Jeong YH,B Liden KP, Antonino MJ,et al.Usefulness of the VerifyNow P2Y 12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.Am Heart J,2012; 164:35-42.
7Ran AK, Pratt C, Berke A, et al. Thrombolysis In Myocardial Infarction (TIMI) trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coil Cardiol,1988;l 1:1-11.
8Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary svndromes.N En-,l J Med.2009:361 (11): 1045-1057.
9Story RF, Angiolillo DJ,Patil SB,et al.Inhibitory effects of ticagrelor compared with clopidogrel on platlet function in patients with acute coronary syndromes:the PLATO(PLATelet inhibition and patient Outcomes) PLATLET substudy, J Am Coil Cardiol,2010;56(18): 1456- 1462.
10O Gara PT,FG K,DD A,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial inearction :a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,Circulation,2013; 127(4):e362-425.

二级参考文献6

1Huber K, Hamad B,Kirkparick P. Fresh from the pipeline ti- cagrelor. Nat Rev Drug Discov, 2011,10:255-256.
2Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopi dogrel in patients with acute coronary syndromes. N Engl J Med,2009,361,1045-1057.
3Cannon CP, Harrington RA, James S, et al. Comparison of ti- cagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO) :a randomised double-blind study. Lancet, 2010,375 : 283-293.
4James SK,Roe MT, Cannon GP, et al. Ticagrelor versus clopi dogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective random ized PLATelet inhibition and patient outcomes(PLATO) Tri- al. BMJ ,2011,342 :d3527.
5Held C, ]ksenblad N, Bassand JP, et al. Ticagrelor versus clopi dogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery-results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coil Car- diol, 2011,57 : 672-684.
6Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias andelinical bradyarrhythmicevents in pa tients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(platelet inhibition and patient out- comes)trial. J Am Coil Cardiol,2011,57: 1908-1916.